MK-1200 for Advanced Solid Tumors

Phase 1

• Conditions: Advanced solid tumor; MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2023-508684-68-00
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-12-22
• Last Update Posted: 21 August 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 247

Inclusion Criteria

Confirmed advanced (unresectable and/or metastatic) solid tumor: gastric cancer (including gastroesophageal junction cancer), esophageal cancer, biliary tract cancer, or pancreatic ductal adenocarcinoma, Participants who experienced Adverse Events (AEs) due to previous anticancer therapies must have recovered to < Grade 1 or baseline, Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy, Received and progressed on or after 1 or 2 prior lines of therapy

Exclusion Criteria

Active severe digestive disease, Known active central nervous system (CNS) metastases and/or carcinomatous meningitis, Active infection requiring systemic therapy, History of known Hepatitis B or known active Hepatitis C viral infection, Have not adequately recovered from major surgery or have ongoing surgical complications, History of major cardiovascular diseases, History of acute myocardial infarction; unstable angina; stroke or transient ischemic attack within 6 months prior to the first dose of study intervention, Cardiac pacemaker use, Diabetes or hypertension that cannot be controlled by medication, HIV-infected participants with a history of Kaposi’s sarcoma and/or Multicentric Castleman’s Disease, Received prior systemic anticancer therapy including investigational agents within 4 weeks before study intervention, Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids, Known additional malignancy that is progressing or has required active treatment within the past 2 years

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified